UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations

/in , , , /by

New phase 1/2 results published in the Journal of Clinical Oncology provide further evidence of the clinical activity of bavdegalutamide (ARV-110), an experimental androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that specific AR mutations may help identify patients most likely to benefit from this treatment. Unlike conventional […]

Read more

UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001

/in , , , /by

Updated results from the TheraPb phase 1 trial, presented at ESMO 2026, provide longer-term follow-up for ²¹²Pb-ADVC001, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 22 heavily pretreated patients across different dose levels and treatment schedules. With an additional 12 months of observation and a median follow-up of […]

Read more

UPDATE: EIK1003 Plus Abiraterone Shows Early Activity in HRR-Mutated Prostate Cancer

/in , , , /by

New results provide updated safety and efficacy data for EIK1003 (formerly IMP1734), an investigational selective PARP1 inhibitor, in combination with abiraterone and prednisone in patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations. Unlike conventional PARP inhibitors, EIK1003 selectively targets PARP1 while largely sparing PARP2, potentially reducing the hematological toxicity associated with […]

Read more

UPDATE: CONVERGE-01 Trial Reports 83% PSA50 Response in Patients Without Prior Lu-PSMA

/in , , /by

New results from the phase 2 CONVERGE-01 trial,  show preliminary antitumor activity of CONV01-α, an experimental PSMA-targeted alpha therapy, in patients with metastatic androgen pathway inhibitor-resistant prostate cancer (mCRPC) who had not previously received Lu-PSMA radioligand therapy. CONV01-α, also known as ²²⁵Ac-rosopatamab tetraxetan, combines the alpha-emitting isotope actinium-225 with a monoclonal antibody targeting PSMA. Unlike […]

Read more

UPDATE: Gedatolisib Plus Darolutamide Shows Activity in mCRPC

/in , , , /by

Updated results from the phase 1/2 CELC-G-201 trial (we talked about it in this previous article) provide new evidence of antitumor activity for gedatolisib combined with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs). Gedatolisib inhibits the PI3K–AKT–mTOR signaling pathway, which can contribute to resistance to […]

Read more

Phase 2 ExBAT Trial: AR Amplification Linked to Poorer Outcomes With Alternating Testosterone and Darolutamide

/in , , /by

New biomarker findings from the phase 2 ExBAT trial, suggest that androgen receptor (AR) amplification may be associated with poorer outcomes in patients receiving alternating bipolar androgen therapy (BAT) and darolutamide for metastatic castration-resistant prostate cancer (mCRPC). ExBAT/LACOG 0620 investigated an experimental strategy combining periods of supraphysiological testosterone exposure with subsequent androgen receptor inhibition. Patients […]

Read more

Phase 2 Trial: DLL3 PET Reveals Tumor Heterogeneity in Neuroendocrine Prostate Cancer

/in , , /by

New findings suggest that an experimental PET imaging technique targeting DLL3 could help identify neuroendocrine prostate cancer (NEPC) lesions and reveal important differences between metastases within the same patient. Neuroendocrine prostate cancer is an aggressive form of the disease that can emerge following prolonged treatment with androgen receptor-targeted therapies. These tumors frequently show reduced PSMA […]

Read more

ZZ-FIRST Trial: Adding Talazoparib to Enzalutamide Shows No Clear Additional Benefit in Metastatic Prostate Cancer

/in , , /by

A randomised phase 2 trial published in Nature Medicine has investigated whether adding the PARP inhibitor talazoparib to enzalutamide and androgen deprivation therapy (ADT) can improve outcomes in men with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), regardless of their homologous recombination repair (HRR) mutation status. The study, known as ZZ-FIRST enrolled 54 patients across eight […]

Read more

Phase 2 Trial Tests Tinengotinib With Darolutamide or Enzalutamide in Hormone-Resistant Prostate Cancer

/in , , /by

A newly registered phase 2 clinical trial will investigate whether combining tinengotinib (TT-00420) with darolutamide or enzalutamide can improve disease control in men with metastatic castration-resistant prostate cancer (mCRPC). Tinengotinib is an oral multikinase inhibitor targeting several pathways involved in cancer growth and survival, including FGFR, JAK, VEGFR and Aurora kinases. Unlike darolutamide and enzalutamide, […]

Read more

Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer

/in , , , /by

A newly registered phase 1/2 clinical trial will investigate whether combining two immunotherapies with complementary mechanisms can improve treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The study, known as JET-201, plans to enrol 107 patients in the United States and South Korea. The combination brings together pasritamig (JNJ-78278343), a bispecific antibody designed […]

Read more